TRANSPOD
22.7.2022 08:02:07 CEST | Business Wire | Press release
TransPod , the startup that is building the world’s leading ultra-high-speed ground transportation system (the TransPod Line ) to disrupt and redefine passenger and cargo transportation, unveiled the FluxJet, an industry-defining innovation that transforms the way we live, work, and travel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220721005004/en/
Based on groundbreaking innovations in propulsion and fossil-fuel-free clean energy systems, the FluxJet is a fully electric vehicle that is effectively a hybrid between an aircraft and a train. Featuring technological leaps in contactless power transmission and a new field of physics called veillance flux , the FluxJet travels in a protected guideway at over 1000 km/h – faster than a jet and three times as fast as a high-speed train.
The FluxJet will operate exclusively on the TransPod Line, a network system with stations in key locations and major cities, featuring high-frequency departures designed to enable fast, affordable, and safe travel. Most recently, TransPod confirmed $550M US finance and announced the next phase of an $18B US infrastructure project to build the TransPod Line to connect the cities of Calgary and Edmonton in Alberta, Canada. Preliminary construction work, including the environmental impact assessment, has begun. This critical project will create up to 140,000 jobs and add $19.2B to the region’s GDP throughout construction. Once the TransPod Line is in operation, it will cost passengers approximately 44 per cent less than a plane ticket to travel the corridor and reduce CO2 emissions by 636,000 tonnes per year.
“All the hard work over the past few years has led to this milestone moment where talk is becoming a reality. The technology is proven, and we have the confidence of investors, governments, and partners to continue pushing forward to redefine transportation effectively,” said Sebastien Gendron, co-founder and CEO, TransPod.
At TransPod’s unveiling event in Toronto, a scaled-down FluxJet was featured in a live demonstration showing its flight capabilities. The almost 1-tonne FluxJet vehicle demonstrated a take-off, travel, and landing procedure within its guideway. Event and demo footage can be found here .
“This milestone is a major leap forward,” said Ryan Janzen, co-founder and CTO, TransPod. “The FluxJet is at a nexus of scientific research, industrial development, and massive infrastructure to address passengers' needs and reduce our dependence on fossil-fuel-heavy jets and highways.”
“TransPod completely changes the game with ultra high-speed, zero-emission passenger travel and freight transportation between major gateway cities,” said Yung Wu, CEO of MaRS Discovery District. “It is time for bold action from our policymakers, investors, and operators to support the commercialization of made-in-Canada innovations like TransPod, to win in the multi-trillion dollar global innovation economy."
“The FluxJet is a first for Canadian innovation and is the next great infrastructure project to be brought worldwide,” said Janzen. “The TransPod Line is being developed in collaboration with our partners in Europe, USA, and beyond, including universities, research centres, the aerospace industry, architecture, railway, and construction partners.”
TransPod’s FluxJet unveiling was made possible with the support and collaboration of the Building Trades of Alberta , Canada’s Building Trades Unions , Dassault Systèmes , DHL Express , MaRS , Ikos Consulting , REC Architecture , and SADE Engineering .
About TransPod Inc.
TransPod’s goal is to disrupt and redefine commercial transportation between major cities in developed and emerging markets. The startup was founded in 2015 to build the world’s leading tube-transportation system (the TransPod Line ) to connect people, cities, and businesses with high-speed transportation that is affordable and environmentally sustainable. TransPod Inc. is headquartered in Toronto, Canada and has affiliate companies in Alberta, France, and the UAE. Visit www.transpod.com to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom